相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models
Oliver Politz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu et al.
PLOS ONE (2015)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
Melissa Dumble et al.
PLOS ONE (2014)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics
Qingping Zeng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
Craig Cherrin et al.
CANCER BIOLOGY & THERAPY (2010)
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
Mark R. Lackner
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Y Luo et al.
MOLECULAR CANCER THERAPEUTICS (2005)
分享论文
